 Sharon Grady
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Nicotinic | 45 | 2017 | 321 | 5.960 |
Why?
| | Nicotinic Agonists | 20 | 2016 | 136 | 2.700 |
Why?
| | Dopamine | 26 | 2017 | 283 | 2.540 |
Why?
| | Nicotine | 29 | 2016 | 331 | 1.750 |
Why?
| | Corpus Striatum | 14 | 2014 | 179 | 1.240 |
Why?
| | Synaptosomes | 14 | 2014 | 32 | 0.980 |
Why?
| | Conotoxins | 10 | 2012 | 16 | 0.890 |
Why?
| | Nicotinic Antagonists | 10 | 2013 | 35 | 0.730 |
Why?
| | Presynaptic Terminals | 5 | 2014 | 86 | 0.680 |
Why?
| | Central Nervous System | 2 | 2013 | 281 | 0.620 |
Why?
| | Varenicline | 2 | 2015 | 28 | 0.540 |
Why?
| | Parkinsonian Disorders | 3 | 2013 | 43 | 0.530 |
Why?
| | Acetylcholine | 10 | 2013 | 204 | 0.520 |
Why?
| | Mesencephalon | 6 | 2011 | 64 | 0.510 |
Why?
| | Pyridines | 13 | 2014 | 605 | 0.500 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 3 | 2013 | 93 | 0.480 |
Why?
| | Protein Subunits | 11 | 2012 | 226 | 0.470 |
Why?
| | Mice | 43 | 2017 | 18339 | 0.460 |
Why?
| | Dose-Response Relationship, Drug | 15 | 2015 | 2027 | 0.450 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 11 | 2014 | 279 | 0.450 |
Why?
| | Dyskinesia, Drug-Induced | 2 | 2012 | 14 | 0.450 |
Why?
| | Levodopa | 2 | 2012 | 41 | 0.450 |
Why?
| | Antiparkinson Agents | 2 | 2012 | 41 | 0.450 |
Why?
| | Mice, Inbred C57BL | 28 | 2015 | 5992 | 0.440 |
Why?
| | Mice, Knockout | 17 | 2014 | 3121 | 0.430 |
Why?
| | Nerve Tissue Proteins | 3 | 2012 | 592 | 0.430 |
Why?
| | Dyskinesias | 1 | 2013 | 20 | 0.400 |
Why?
| | Synaptic Transmission | 4 | 2012 | 290 | 0.390 |
Why?
| | Animals | 49 | 2017 | 38058 | 0.390 |
Why?
| | Benzazepines | 2 | 2013 | 35 | 0.380 |
Why?
| | Dopamine Agents | 1 | 2012 | 22 | 0.360 |
Why?
| | Quinoxalines | 1 | 2012 | 65 | 0.340 |
Why?
| | Neurons | 8 | 2017 | 1640 | 0.300 |
Why?
| | Habenula | 1 | 2009 | 13 | 0.290 |
Why?
| | Gene Expression | 2 | 2015 | 1490 | 0.280 |
Why?
| | Autoradiography | 5 | 2015 | 64 | 0.270 |
Why?
| | Parkinson Disease | 3 | 2011 | 600 | 0.270 |
Why?
| | Cotinine | 4 | 2016 | 79 | 0.240 |
Why?
| | Brain | 9 | 2015 | 2933 | 0.220 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 6 | 2014 | 59 | 0.220 |
Why?
| | Mice, Transgenic | 10 | 2017 | 2182 | 0.190 |
Why?
| | Superior Colliculi | 2 | 2012 | 44 | 0.180 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1094 | 0.180 |
Why?
| | Substantia Nigra | 5 | 2013 | 63 | 0.170 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 496 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 5 | 2014 | 192 | 0.160 |
Why?
| | Proteome | 2 | 2016 | 518 | 0.160 |
Why?
| | Tritium | 5 | 2012 | 68 | 0.160 |
Why?
| | Cerebral Cortex | 3 | 2016 | 464 | 0.150 |
Why?
| | Mice, Mutant Strains | 5 | 2013 | 299 | 0.150 |
Why?
| | Quinolizines | 4 | 2014 | 9 | 0.150 |
Why?
| | Azocines | 4 | 2014 | 8 | 0.150 |
Why?
| | Alkaloids | 4 | 2014 | 28 | 0.150 |
Why?
| | Binding Sites | 5 | 2015 | 1329 | 0.140 |
Why?
| | Mecamylamine | 3 | 2013 | 6 | 0.140 |
Why?
| | Behavior, Animal | 5 | 2013 | 519 | 0.130 |
Why?
| | GPI-Linked Proteins | 1 | 2017 | 80 | 0.130 |
Why?
| | Smoking Cessation | 2 | 2013 | 439 | 0.130 |
Why?
| | Gene Knock-In Techniques | 3 | 2013 | 61 | 0.130 |
Why?
| | Neostriatum | 3 | 2014 | 37 | 0.120 |
Why?
| | Mutation | 4 | 2012 | 4089 | 0.110 |
Why?
| | Body Temperature | 3 | 2012 | 229 | 0.110 |
Why?
| | GABA-B Receptor Agonists | 1 | 2014 | 5 | 0.110 |
Why?
| | Receptors, GABA-B | 1 | 2014 | 10 | 0.110 |
Why?
| | Motor Activity | 4 | 2013 | 721 | 0.110 |
Why?
| | Baclofen | 1 | 2014 | 21 | 0.110 |
Why?
| | Nucleus Accumbens | 2 | 2013 | 132 | 0.100 |
Why?
| | Saccharin | 1 | 2013 | 8 | 0.100 |
Why?
| | Potassium | 2 | 2004 | 152 | 0.100 |
Why?
| | Central Nervous System Sensitization | 1 | 2012 | 5 | 0.100 |
Why?
| | Dopaminergic Neurons | 1 | 2013 | 67 | 0.100 |
Why?
| | Reward | 2 | 2013 | 247 | 0.090 |
Why?
| | Tobacco Use Cessation | 1 | 2013 | 28 | 0.090 |
Why?
| | Benserazide | 1 | 2012 | 1 | 0.090 |
Why?
| | Hydroxydopamines | 1 | 2012 | 4 | 0.090 |
Why?
| | Molecular Structure | 2 | 2013 | 499 | 0.090 |
Why?
| | Hexamethonium | 1 | 2012 | 5 | 0.090 |
Why?
| | Ondansetron | 1 | 2012 | 19 | 0.090 |
Why?
| | Visual Pathways | 1 | 2012 | 61 | 0.090 |
Why?
| | Receptors, Serotonin, 5-HT3 | 1 | 2012 | 16 | 0.090 |
Why?
| | Bungarotoxins | 2 | 2012 | 45 | 0.090 |
Why?
| | Inhibitory Concentration 50 | 1 | 2012 | 91 | 0.090 |
Why?
| | Protein Binding | 7 | 2013 | 2273 | 0.090 |
Why?
| | Hypothermia | 1 | 2012 | 52 | 0.080 |
Why?
| | Rubidium Radioisotopes | 3 | 2012 | 9 | 0.080 |
Why?
| | Visual Cortex | 1 | 2011 | 84 | 0.080 |
Why?
| | Male | 18 | 2014 | 72315 | 0.080 |
Why?
| | Ventral Tegmental Area | 1 | 2011 | 60 | 0.080 |
Why?
| | RNA, Messenger | 4 | 2017 | 2832 | 0.080 |
Why?
| | In Vitro Techniques | 4 | 2014 | 1047 | 0.080 |
Why?
| | Rats | 5 | 2013 | 5597 | 0.080 |
Why?
| | Locomotion | 1 | 2010 | 105 | 0.080 |
Why?
| | Tegmentum Mesencephali | 1 | 2009 | 5 | 0.070 |
Why?
| | Elasticity | 1 | 2010 | 184 | 0.070 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 194 | 0.070 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2009 | 109 | 0.070 |
Why?
| | Receptors, Dopamine D2 | 1 | 2009 | 93 | 0.070 |
Why?
| | Synapses | 1 | 2012 | 439 | 0.070 |
Why?
| | Receptors, Dopamine | 2 | 2010 | 19 | 0.070 |
Why?
| | Pyrrolidines | 1 | 2009 | 125 | 0.070 |
Why?
| | Epilepsy, Frontal Lobe | 1 | 2007 | 2 | 0.070 |
Why?
| | Perforant Pathway | 1 | 2007 | 3 | 0.070 |
Why?
| | MPTP Poisoning | 2 | 2007 | 6 | 0.070 |
Why?
| | Dystonic Disorders | 1 | 2007 | 27 | 0.070 |
Why?
| | Female | 15 | 2016 | 78271 | 0.070 |
Why?
| | Radioligand Assay | 3 | 2014 | 37 | 0.060 |
Why?
| | Drug Tolerance | 1 | 2007 | 100 | 0.060 |
Why?
| | Gene Deletion | 2 | 2009 | 389 | 0.060 |
Why?
| | Neural Pathways | 1 | 2009 | 311 | 0.060 |
Why?
| | Breeding | 1 | 2007 | 63 | 0.060 |
Why?
| | Arousal | 1 | 2007 | 157 | 0.060 |
Why?
| | Genotype | 1 | 2012 | 1833 | 0.060 |
Why?
| | Protein Conformation | 1 | 2010 | 946 | 0.060 |
Why?
| | Iodine Radioisotopes | 4 | 2012 | 136 | 0.060 |
Why?
| | Behavioral Research | 1 | 2006 | 35 | 0.060 |
Why?
| | Thalamus | 2 | 2009 | 125 | 0.060 |
Why?
| | Cell Membrane | 2 | 2012 | 706 | 0.060 |
Why?
| | Proteomics | 1 | 2013 | 1195 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2009 | 2527 | 0.060 |
Why?
| | Piperazines | 2 | 2013 | 381 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2005 | 154 | 0.060 |
Why?
| | Long-Term Potentiation | 1 | 2007 | 200 | 0.060 |
Why?
| | Receptors, Presynaptic | 1 | 2004 | 9 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2006 | 267 | 0.050 |
Why?
| | Drug Interactions | 3 | 2012 | 398 | 0.050 |
Why?
| | Cell Line | 1 | 2010 | 2882 | 0.050 |
Why?
| | Anxiety | 1 | 2011 | 1109 | 0.050 |
Why?
| | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2003 | 4 | 0.050 |
Why?
| | Binding, Competitive | 4 | 2005 | 193 | 0.050 |
Why?
| | Neurons, Efferent | 1 | 2003 | 9 | 0.050 |
Why?
| | Avoidance Learning | 1 | 2003 | 64 | 0.050 |
Why?
| | Tobacco Use Disorder | 2 | 2016 | 218 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2608 | 0.050 |
Why?
| | Nomifensine | 1 | 2002 | 2 | 0.050 |
Why?
| | Desipramine | 1 | 2002 | 10 | 0.050 |
Why?
| | Inferior Colliculi | 1 | 2002 | 15 | 0.050 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 2 | 2012 | 6 | 0.040 |
Why?
| | Patch-Clamp Techniques | 2 | 2013 | 289 | 0.040 |
Why?
| | Dopamine Agonists | 2 | 2013 | 42 | 0.040 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2012 | 107 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4557 | 0.040 |
Why?
| | Iodine Isotopes | 2 | 2012 | 5 | 0.040 |
Why?
| | Down-Regulation | 2 | 2014 | 627 | 0.040 |
Why?
| | Ganglionic Stimulants | 2 | 2010 | 15 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2011 | 1306 | 0.030 |
Why?
| | Time Factors | 4 | 2014 | 7173 | 0.030 |
Why?
| | Up-Regulation | 2 | 2012 | 851 | 0.030 |
Why?
| | Saimiri | 2 | 2007 | 9 | 0.030 |
Why?
| | Hippocampus | 2 | 2012 | 965 | 0.030 |
Why?
| | Action Potentials | 2 | 2011 | 506 | 0.030 |
Why?
| | Species Specificity | 2 | 2007 | 574 | 0.030 |
Why?
| | Humans | 8 | 2017 | 144759 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 744 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2017 | 427 | 0.030 |
Why?
| | Autoreceptors | 1 | 2014 | 4 | 0.030 |
Why?
| | Ligands | 2 | 2009 | 673 | 0.030 |
Why?
| | Pyrethrins | 1 | 2014 | 8 | 0.030 |
Why?
| | Potassium Chloride | 1 | 2014 | 40 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 69 | 0.030 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 1 | 2013 | 18 | 0.030 |
Why?
| | Electrophysiological Phenomena | 1 | 2013 | 60 | 0.020 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2013 | 58 | 0.020 |
Why?
| | Dihydro-beta-Erythroidine | 1 | 2013 | 6 | 0.020 |
Why?
| | Neurotransmitter Agents | 1 | 2013 | 82 | 0.020 |
Why?
| | Extracellular Space | 1 | 2013 | 120 | 0.020 |
Why?
| | Amphetamine | 1 | 2013 | 38 | 0.020 |
Why?
| | Drug Partial Agonism | 1 | 2013 | 2 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2014 | 252 | 0.020 |
Why?
| | Olfactory Bulb | 1 | 2014 | 97 | 0.020 |
Why?
| | Dystonia | 1 | 2012 | 28 | 0.020 |
Why?
| | Self Administration | 1 | 2013 | 124 | 0.020 |
Why?
| | Tropanes | 1 | 2012 | 5 | 0.020 |
Why?
| | Diencephalon | 1 | 2012 | 14 | 0.020 |
Why?
| | Alkylation | 1 | 2012 | 27 | 0.020 |
Why?
| | Dizocilpine Maleate | 1 | 2012 | 24 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2012 | 30 | 0.020 |
Why?
| | Point Mutation | 1 | 2013 | 243 | 0.020 |
Why?
| | GABAergic Neurons | 1 | 2012 | 35 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2013 | 451 | 0.020 |
Why?
| | Oxidopamine | 1 | 2011 | 14 | 0.020 |
Why?
| | Sympatholytics | 1 | 2011 | 11 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2013 | 594 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2013 | 454 | 0.020 |
Why?
| | Microdissection | 1 | 2011 | 15 | 0.020 |
Why?
| | Bicuculline | 1 | 2011 | 18 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2011 | 19 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1187 | 0.020 |
Why?
| | Atropine | 1 | 2011 | 37 | 0.020 |
Why?
| | Conditioning, Operant | 1 | 2011 | 97 | 0.020 |
Why?
| | Muscarinic Antagonists | 1 | 2011 | 30 | 0.020 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2011 | 71 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2011 | 165 | 0.020 |
Why?
| | Cell Size | 1 | 2011 | 92 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2012 | 340 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1054 | 0.020 |
Why?
| | Hyperkinesis | 1 | 2010 | 16 | 0.020 |
Why?
| | Cell Count | 1 | 2011 | 320 | 0.020 |
Why?
| | Functional Laterality | 1 | 2011 | 241 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2011 | 196 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 576 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2011 | 276 | 0.020 |
Why?
| | Catalepsy | 1 | 2009 | 1 | 0.020 |
Why?
| | Muscle Rigidity | 1 | 2009 | 3 | 0.020 |
Why?
| | Quinpirole | 1 | 2009 | 10 | 0.020 |
Why?
| | Cholinergic Fibers | 1 | 2009 | 19 | 0.020 |
Why?
| | Epilepsy, Generalized | 1 | 2009 | 19 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2012 | 498 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1472 | 0.020 |
Why?
| | Brain Chemistry | 1 | 2009 | 116 | 0.020 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2008 | 20 | 0.020 |
Why?
| | Tremor | 1 | 2009 | 98 | 0.020 |
Why?
| | Seizures | 1 | 2012 | 460 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2009 | 381 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2009 | 304 | 0.020 |
Why?
| | Interneurons | 1 | 2009 | 128 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 173 | 0.020 |
Why?
| | Electrophysiology | 1 | 2008 | 218 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2009 | 570 | 0.020 |
Why?
| | Mice, Neurologic Mutants | 1 | 2007 | 20 | 0.020 |
Why?
| | Models, Chemical | 1 | 2009 | 269 | 0.020 |
Why?
| | Temperature | 1 | 2011 | 679 | 0.020 |
Why?
| | Xenopus | 1 | 2007 | 89 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2008 | 205 | 0.020 |
Why?
| | Mental Disorders | 1 | 2016 | 1168 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1370 | 0.010 |
Why?
| | Calcium | 1 | 2012 | 1183 | 0.010 |
Why?
| | Kinetics | 1 | 2009 | 1627 | 0.010 |
Why?
| | Pyrimidines | 1 | 2009 | 532 | 0.010 |
Why?
| | Azetidines | 1 | 2005 | 45 | 0.010 |
Why?
| | Water | 1 | 2008 | 469 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4154 | 0.010 |
Why?
| | Receptors, Cholinergic | 1 | 2004 | 41 | 0.010 |
Why?
| | Gene Targeting | 1 | 2003 | 82 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2005 | 561 | 0.010 |
Why?
| | Tetracycline | 1 | 2003 | 13 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2003 | 319 | 0.010 |
Why?
| | Reflex, Startle | 1 | 2003 | 76 | 0.010 |
Why?
| | Electroshock | 1 | 2003 | 145 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2003 | 113 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2003 | 178 | 0.010 |
Why?
| | Transgenes | 1 | 2003 | 189 | 0.010 |
Why?
| | Models, Biological | 1 | 2006 | 1821 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2003 | 905 | 0.010 |
Why?
| | Aged | 1 | 2007 | 25913 | 0.000 |
Why?
|
|
Grady's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|